Threshold Pharmaceuticals, Inc., based in South San Francisco,
California, is a research-driven biotechnology company dedicated to the discovery and development of tumor targeted therapies to improve the lives of patients with cancer.
- December 6, 2014
- Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting
- November 25, 2014
- Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in December 2014
- November 17, 2014
- Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma